Plasma proteomics analyses shed light on potential molecular mechanisms and suggested several candidate biomarkers, such as PRDX6, FN1, and SERPINB9, for the clinical prevention, diagnosis, or management of overweight PCOS patients. The gene discussed is FN1; the disease is polycystic ovary syndrome.